Search - tctmd.com

Displaying 1 - 20 of 86

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2017

Shelley Wood

November 29, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

Presentation Cardiovascular Interventions 2017

DAPT Duration After Stenting: An Updated Appraisal

Presenter: Dean J. Kereiakes

November 09, 2017

Presentation TCT 2017

SENIOR and Shorter DAPT Studies: Highlights Summary

Presenter: Martin B. Leon, Marco Valgimigli, Olivier Varenne

November 01, 2017

Presentation TCT 2017

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

Presenter: Robert A. Harrington, Kurt Huber, Didier Carrié

November 01, 2017

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Todd Neale

November 01, 2017

Presentation TCT 2017

What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants

Presenter: Robert A. Harrington, Kurt Huber, Freek W.A. Verheugt

November 01, 2017

News Conference News TCT 2017

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Michael O'Riordan

November 01, 2017

Presentation TCT 2017

REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS

Presenter: Robert A. Harrington, Gregg W. Stone, Harry Suryapranata

November 01, 2017

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Three

Shelley Wood

November 01, 2017

Presentation TCT 2017

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI

Presenter: Robert A. Harrington, Gregg W. Stone, Elvin Kedhi

November 01, 2017

Presentation TCT 2017

SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years

Presenter: Robert A. Harrington, Gregg W. Stone, Olivier Varenne

November 01, 2017

Presentation TCT 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

FDA Perspectives on Short DAPT IDE Trials

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee

October 31, 2017

Presentation TCT 2017

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Standard vs Novel DES and DAPT Duration

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Ajay J. Kirtane

October 31, 2017

Presentation TCT 2017

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Appropriate Patients and DAPT Duration

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Marie-Claude Morice

October 31, 2017

Advertisement

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

TCTMD’s Top 10 Most Popular Stories for November 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

DAPT Duration After Stenting: An Updated Appraisal

SENIOR and Shorter DAPT Studies: Highlights Summary

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS

Live From Denver: TCT 2017, Day Three

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI

SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

FDA Perspectives on Short DAPT IDE Trials

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Standard vs Novel DES and DAPT Duration

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Appropriate Patients and DAPT Duration

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content